Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs).

MLA

Oberguggenberger, Anne, et al. “Is the Toxicity of Adjuvant Aromatase Inhibitor Therapy Underestimated? Complementary Information from Patient-Reported Outcomes (PROs).” Breast Cancer Research and Treatment, vol. 128, no. 2, July 2011, pp. 553–61. EBSCOhost, https://doi.org/10.1007/s10549-011-1378-5.

APA

Oberguggenberger, A., Hubalek, M., Sztankay, M., Meraner, V., Beer, B., Oberacher, H., Giesinger, J., Kemmler, G., Egle, D., Gamper, E.-M., Sperner-Unterweger, B., & Holzner, B. (2011). Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Research and Treatment, 128(2), 553–561. https://doi.org/10.1007/s10549-011-1378-5

Chicago

Oberguggenberger, Anne, Michael Hubalek, Monika Sztankay, Verena Meraner, Beate Beer, Herbert Oberacher, Johannes Giesinger, et al. 2011. “Is the Toxicity of Adjuvant Aromatase Inhibitor Therapy Underestimated? Complementary Information from Patient-Reported Outcomes (PROs).” Breast Cancer Research and Treatment 128 (2): 553–61. doi:10.1007/s10549-011-1378-5.